Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 35HER2-positive Breast Cancer 3Brain Neoplasms 3Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Motor Activity 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Invasive Breast Cancer 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Metastatic Breast Cancer × pertuzumab × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡